Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot study

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Lee, Hyunah ^a   Park, Jae Berm ^a   Lee, Sanghoon ^a   Baek, Soyoung ^a   Kim, HyunSoo ^b   Kim, Sung Joo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b FCB Pharmicell CoLtd   (South Korea)

Author keywords

Donor MSC; Immune response; Intra osseous injection; Living Donor Kidney Transplantation (LDKT)

Indexed keywords

CREATININE; IMMUNOGLOBULIN; INTERLEUKIN 10; MESSENGER RNA; STEROID; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DRUG PULSE THERAPY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INJECTION; INTRAOSSEUS INJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIXED LYMPHOCYTE REACTION; OUTCOME ASSESSMENT; PATIENT SAFETY; PILOT STUDY; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SHORT TANDEM REPEAT; STEROID THERAPY;

ADULT; BONE MARROW CELLS; CELL PROLIFERATION; CREATININE; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; INFUSIONS, INTRAOSSEOUS; INTERLEUKIN-10; KIDNEY TRANSPLANTATION; LIVING DONORS; LYMPHOCYTES; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PILOT PROJECTS; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84875928018     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-96     Document Type: Article

References (23)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002, 346:580-590. 10.1056/NEJMra011295, 11856798.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383. 10.1111/j.1600-6143.2004.00332.x, 14961990.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326-2333. 10.1056/NEJMoa020009, 14668458.
4. Heino TJ, Hentunen TA, Vaananen HK. Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res 2004, 294:458-468. 10.1016/j.yexcr.2003.11.016, 15023534.
5. Janderova L, McNeil M, Murrell AN, Mynatt RL, Smith SR. Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obes Res 2003, 11:65-74. 10.1038/oby.2003.11, 12529487.
6. Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G, Buschmann MD, Henderson JE. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem 2005, 280:20509-20515. 10.1074/jbc.M410148200, 15781473.
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822. 10.1182/blood-2004-04-1559, 15494428.
8. Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A, Frassoni F, Bartolome ST, Sambuceti G, Traggiai E, Uccelli A. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011, 108:17384-17389. 10.1073/pnas.1103650108, 3198360, 21960443.
9. Choi YS, Jeong JA, Lim DS. Mesenchymal stem cell-mediated immature dendritic cells induce regulatory T cell-based immunosuppressive effect. Immunol Invest 2012, 41:214-229. 10.3109/08820139.2011.619022, 22017637.
10. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441. 10.1016/S0140-6736(04)16104-7, 15121408.
11. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586. 10.1016/S0140-6736(08)60690-X, 18468541.
12. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397. 10.1097/01.tp.0000214462.63943.14, 16732175.
13. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasa M, Golay J, Noris M, Remuzzi G. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011, 6:412-422. 10.2215/CJN.04950610, 3052234, 20930086.
14. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012, 307:1169-1177. 10.1001/jama.2012.316, 22436957.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
16. Itakura S, Asari S, Rawson J, Ito T, Todorov I, Liu CP, Sasaki N, Kandeel F, Mullen Y. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007, 7:336-346. 10.1111/j.1600-6143.2006.01643.x, 17283484.
17. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81:1589-1595. 10.1097/01.tp.0000209919.90630.7b, 16770249.
18. Hoogduijn MJ, Popp FC, Grohnert A, Crop MJ, van Rhijn M, Rowshani AT, Eggenhofer E, Renner P, Reinders ME, Rabelink TJ, van der Laan LJ, Dor FJ, Ijzermans JN, Genever PG, Lange C, Durrbach A, Houtgraaf JH, Christ B, Seifert M, Shagidulin M, Donckier V, Deans R, Ringden O, Perico N, Remuzzi G, Bartholomew A, Schlitt HJ, Weimar W, Baan CC, Dahlke MH. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010, 90:124-126.
19. Castello S, Podesta M, Menditto VG, Ibatici A, Pitto A, Figari O, Scarpati D, Magrassi L, Bacigalupo A, Piaggio G, Frassoni F. Intra-bone marrow injection of bone marrow and cord blood cells: an alternative way of transplantation associated with a higher seeding efficiency. Exp Hematol 2004, 32:782-787. 10.1016/j.exphem.2004.05.026, 15308330.
20. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012, 67:1-8.
21. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010, 90:1312-1320. 10.1097/TP.0b013e3181fed001, 21042238.
22. Kim YH, Wee YM, Choi MY, Lim DG, Kim SC, Han DJ. Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 2011, 17:697-708. 3146595, 21365122.
23. Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, Nam HY, Kim YH, Kim B, Park CG. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 2009, 41:315-324. 10.3858/emm.2009.41.5.035, 2701980, 19307751.